Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E Grimm; Willem Witlox; Robert Wolff; Annette Chalker; Mickael Hiligsmann; Ben Wijnen; Charlotte Ahmadu; Steve Ryder; Nigel Armstrong; Steven Duffy; Isabel Syndikus; Jos Kleijnen; Manuela A Joore

doi:10.1007/s40273-022-01144-8

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E Grimm^*, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen, Manuela A Joore

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Original language	English
Pages (from-to)	575-575
Number of pages	1
Journal	Pharmacoeconomics
Volume	40
Issue number	5
Early online date	1 Apr 2022
DOIs	https://doi.org/10.1007/s40273-022-01144-8
Publication status	Published - May 2022

Access to Document

10.1007/s40273-022-01144-8Licence: CC BY-NC

1 (Systematic) Review article

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Grimm, S. E., Witlox, W., Wolff, R., Chalker, A., Hiligsmann, M., Wijnen, B., Ahmadu, C., Ryder, S., Armstrong, N., Duffy, S., Syndikus, I., Kleijnen, J. & Joore, M. A., May 2022, In: Pharmacoeconomics. 40, 5, p. 509-518 10 p.
Research output: Contribution to journal › (Systematic) Review article › peer-review

Open Access

Cite this

Grimm, S. E., Witlox, W., Wolff, R., Chalker, A., Hiligsmann, M., Wijnen, B., Ahmadu, C., Ryder, S., Armstrong, N., Duffy, S., Syndikus, I., Kleijnen, J., & Joore, M. A. (2022). Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 40(5), 575-575. https://doi.org/10.1007/s40273-022-01144-8

@article{256b1a9aba224eb09ab52c636f159740,

title = "Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and S{\'e}zary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

author = "Grimm, {Sabine E} and Willem Witlox and Robert Wolff and Annette Chalker and Mickael Hiligsmann and Ben Wijnen and Charlotte Ahmadu and Steve Ryder and Nigel Armstrong and Steven Duffy and Isabel Syndikus and Jos Kleijnen and Joore, {Manuela A}",

year = "2022",

month = may,

doi = "10.1007/s40273-022-01144-8",

language = "English",

volume = "40",

pages = "575--575",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "5",

}

Grimm, SE , Witlox, W, Wolff, R, Chalker, A, Hiligsmann, M, Wijnen, B, Ahmadu, C, Ryder, S, Armstrong, N, Duffy, S, Syndikus, I, Kleijnen, J & Joore, MA 2022, 'Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 40, no. 5, pp. 575-575. https://doi.org/10.1007/s40273-022-01144-8

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E ; Witlox, Willem; Wolff, Robert et al.
In: Pharmacoeconomics, Vol. 40, No. 5, 05.2022, p. 575-575.

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

TY - JOUR

T1 - Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Grimm, Sabine E

AU - Witlox, Willem

AU - Wolff, Robert

AU - Chalker, Annette

AU - Hiligsmann, Mickael

AU - Wijnen, Ben

AU - Ahmadu, Charlotte

AU - Ryder, Steve

AU - Armstrong, Nigel

AU - Duffy, Steven

AU - Syndikus, Isabel

AU - Kleijnen, Jos

AU - Joore, Manuela A

PY - 2022/5

Y1 - 2022/5

U2 - 10.1007/s40273-022-01144-8

DO - 10.1007/s40273-022-01144-8

M3 - Erratum / corrigendum / retractions

C2 - 35364758

SN - 1170-7690

VL - 40

SP - 575

EP - 575

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 5

ER -